Award Result:-(ICB/FW/EPSA6/GF-HAPCO/NFMIII/ARV/PH/01/23)
Tender Code: ICB/FW/EPSA6/GF-HAPCO/NFMIII/ARV/PH/01/23
Award Status: Partial Winners List
Award Date: 07/03/2023
Tender Award: Download
Unsuccessful Bidders:
Technical Evaluation Result:
|
|
Company Name: | Document No: OF/TM/ HO-14 | ||||||||||||
| የኢትዮጵያ መድሃኒት አቅራቢ አገልግሎት | ||||||||||||||
| Ethiopian Pharmaceuticals Supply Service (EPSS) | ||||||||||||||
| Title: | Effective date : 21/01/2022 | |||||||||||||
| Official winner list | ||||||||||||||
| Official winner list of tender No : ICB/FW/EPSA6/GF-HAPCO/NFMIII/ARV/PH/01/23 | ||||||||||||||
|
Ser NO |
Description | Unit | Quantity | No of bidders to be awarded | Winner | Currency | Unit FOB price | allocated volume | Payment Term | port of shipment | Delivery Time | Remark | ||
| Supplier | Country | |||||||||||||
| 1 | Dolutegravir (DTG) – 10mg – Tablet (Dispersible) | 90 | 134,894 | 2 | Mylan Laboratories Limited | India | USD | 4.00 | 80,936 | L/C | Mumbai | Within 60- 90 days from L/C opening date | winning price | |
| Macleods Pharmaceuticals Ltd. | India | USD | 4.24 | 53,958 | L/C | Mumbai | Within 60- 90 days from L/C opening date | 2nd least price | ||||||
| 2 |
Lamivudine + Efavirenz +Tenofovir – (300mg + 400mg + 300mg) – Tablet |
30 | 1,508,165 | 2 | Hetero Labs Limited | India | USD | 3.9300 | 904,899 | L/C at sight | Mumbai | Within 60 – 90 days after L/C opening date | winning price | |
| Macleods Pharmaceuticals Ltd. | India | USD | 3.95 | 603,266 | L/C at sight | Delhi | Within 60- 90 days from L/C opening date | 2nd winner | ||||||
| 3 | Lamivudine (3TC) + Dolutegravir (DTG) + Tenofovir (TDF) – (300mg +50mg+300mg) – Tablet | 90 | 5,010,055 | 2 | Mylan Laboratories Ltd. | India | USD | 8.40 | 3,006,033 | L/C | Mumbai | Within 60- 90 days from L/C opening date | winning price | |
| Cipla Limited | India | USD | 8.46 | 2,004,022 | L/C | Mumbai | Within 60- 90 days from L/C opening date | 2nd winner | ||||||
| 4 | Lopinavir + Ritonavir – (100mg + 25mg) – Tablet | 120 | 7,017 | 2 | Hetero Labs Limited | India | USD | 11.50 | 7,017 | L/C at sight | Mumbai | Within 60 – 90 days after L/C opening date | winning price | |
| 5 | Zidovudine – 10mg/ml – Oral Solution | 100 ml | 94,312 | Pending | ||||||||||
| እባክዎ በዚህ ሰነድ ከመጠቀምዎ በፊት ትክክለኛ መሆኑን ያረጋግጡ | OF for Official winner list OF/TM/HO-15, 0, 21/01/2022 | |||||||||||||
| Make sure that this is the correct issue before use | ||||||||||||||
Reasons for Rejection
|
|
Company Name: | Document No: OF/TM/ HO-16 | ||||
| የኢትዮጵያ መድሃኒት አቅራቢ አገልግሎት | ||||||
| Ethiopian Pharmaceuticals Supply Services | ||||||
| Title: | Effective date : 21/01/2022 | |||||
| Reasons for Rejection | Rev. No.: 0 | Page 1 of 1 | ||||
| Tender no: ICB/FW/EPSA6/GF-MOH/NFMIII/ARV/PH/01/23 | ||||||
| Item No | Prdoduct Description | Name of competitor suppliers | Status | Reason of unsuccessfulness | Remark | |
| 2 | Lamivudine + Efavirenz +Tenofovir – (300mg + 400mg + 300mg) – Tablet | Laurus Labs Limited | Unsuccessful | Price incompetence | ||
| Mylan Laboratories Limited | Unsuccessful | |||||
| Lamivudine (3TC) + Dolutegravir (DTG) + Tenofovir (TDF) – (300mg +50mg+300mg) – Tablet | Aurobindo Pharma Limited | Unsuccessful | The Manufacturer site adress was not the same as the one stated Global Fund Supplier/Manufacturer (s) site list | In GF Quality Assurance list ( latest version 171 – 31-Mar-2023) | ||
| Emcure Pharmaceuticals LTD | Unsuccessful | The counter guaranteed bid bond was submited after bid opening date ( April 10,2023) | ||||
| 3 | Hetro Labs Limited | Unsuccessful | Price incompetence | |||
| Lupin Ltd | Unsuccessful | |||||
| Laurus Labs Limited | Unsuccessful | |||||
| Macleods Pharmaceuticals Ltd | Unsuccessful | |||||
| Micro Labs Limited | Unsuccessful | |||||
| Strides Pharma Science Limited | Unsuccessful | |||||
| 4 | Lopinavir + Ritonavir – (100mg + 25mg) – Tablet | Macleods Pharmaceuticals Ltd | Unsuccessful | Not listed in GF list by the issued unit | ||
| 5 | Zidovudine – 10mg/ml – Oral Solution | Pending | ||||
| እባክዎ በዚህ ሰነድ ከመጠቀምዎ በፊት ትክክለኛ መሆኑን ያረጋግጡ | OF for Reasons for Rejection OF/TM/HO-17, 0, 21/01/2022 | |||||
| Make sure that this is the correct issue before use | ||||||
© EPSS All Right Reserved.
Designed and Developed by Rackmint System